Download PDF
Hamostaseologie 2007; 27(05): 319
DOI: 10.1055/s-0037-1616996
Original Article
Schattauer GmbH

Literatur

H. Hölschermann
1   Kardiologie und Angiologie, Medizinische Klinik I, Hochtaunus-Kliniken, Bad Homburg
› Author Affiliations
Further Information

Publication History

Publication Date:
20 January 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Alpert JS, Thygesen K, Antman E. et al. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
    CrossrefPubMedGoogle Scholar
  • 2 Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation 2000; 102: 118-122.
    CrossrefPubMedGoogle Scholar
  • 3 Hamm CW. Guidelines: Acute coronary syndrome (ACS). II: Acute coronary syndrome with ST-elevation. Z Kardiol 2004; 93: 324-341.
    CrossrefPubMedGoogle Scholar
  • 4 Antman EM, Anbe DT, Armstrong PW. et al. ACC/ AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2004; 44: E1-E211.
    CrossrefPubMedGoogle Scholar
  • 5 Bertrand ME, Simoons ML, Fox KA. et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-1840.
    CrossrefPubMedGoogle Scholar
  • 6 Braunwald E, Antman EM, Beasley JW. et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2000; 102: 1193-1209.
    CrossrefPubMedGoogle Scholar
  • 7 Naghavi M, Libby P, Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672.
    CrossrefPubMedGoogle Scholar
  • 8 Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004; 25: 1197-1207.
    CrossrefPubMedGoogle Scholar
  • 9 Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: longterm effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18: 1587-1593.
    CrossrefPubMedGoogle Scholar
  • 10 Schror K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 1998; 3: 247-251.
    CrossrefPubMedGoogle Scholar
  • 11 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
    CrossrefPubMedGoogle Scholar
  • 12 Mehta SR, Yusuf S, Peters RJ. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
    CrossrefPubMedGoogle Scholar
  • 13 Bassand JP, Hamm CW, Ardissino D. et al. Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1640.
    CrossrefPubMedGoogle Scholar
  • 14 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559.
    CrossrefPubMedGoogle Scholar
  • 15 Coller BS, Peerschke EI, Scudder LE. et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338.
    CrossrefPubMedGoogle Scholar
  • 16 Boersma E, Harrington RA, Moliterno DJ. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-198.
    CrossrefPubMedGoogle Scholar
  • 17 Kastrati A, Mehilli J, Neumann FJ. et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538.
    CrossrefPubMedGoogle Scholar
  • 18 Madan M, Tcheng JE. Update on Abciximab readministration during percutaneous coronary interventions. Curr Interv Cardiol Rep 2000; 2: 244-249.
    PubMedGoogle Scholar
  • 19 Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53: 313-325.
    CrossrefPubMedGoogle Scholar
  • 20 Harrington RA, Becker RC, Ezekowitz M. et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 513S-548S.
    CrossrefPubMedGoogle Scholar
  • 21 Oler A, Whooley MA, Oler J. et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811-815.
    CrossrefPubMedGoogle Scholar
  • 22 Cohen M, Demers C, Gurfinkel EP. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-452.
    CrossrefPubMedGoogle Scholar
  • 23 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
    PubMedGoogle Scholar
  • 24 Klein W, Buchwald A, Hillis SE. et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study. Circulation 1997; 96: 61-68.
    CrossrefPubMedGoogle Scholar
  • 25 Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX. I. S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-1562.
    CrossrefPubMedGoogle Scholar
  • 26 Petersen JL, Mahaffey KW, Hasselblad V. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292: 89-96.
    PubMedGoogle Scholar
  • 27 Blazing MA, de Lemos JA, White HD. et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292: 55-64.
    CrossrefPubMedGoogle Scholar
  • 28 Ferguson JJ, Califf RM, Antman EM. et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54.
    PubMedGoogle Scholar
  • 29 Montalescot G, White HD, Gallo R. et al. STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-1017.
    CrossrefPubMedGoogle Scholar
  • 30 Simoons ML, Bobbink IW, Boland J. et al. A dosefinding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004; 43: 2183-2190.
    CrossrefPubMedGoogle Scholar
  • 31 Yusuf S, Mehta SR, Chrolavicius S. et al. Efficacy and saftey of fondaparinux compared to enoxaparin in 20,028 patients with acute coronary syndromes without ST segment elevation. The OASIS (Organization to Assess Strategies in Acute Ischemic Syndromes)-5 Investigators. N Engl J Med 2006; 354: 1464-1476.
    CrossrefPubMedGoogle Scholar
  • 32 Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999; 353: 429-438.
    CrossrefPubMedGoogle Scholar
  • 33 A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996; 335: 775-782.
    CrossrefPubMedGoogle Scholar
  • 34 Shah PB, Ahmed WH, Ganz P. et al. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J Am Coll Cardiol 1997; 30: 1264-1269.
    CrossrefPubMedGoogle Scholar
  • 35 Bittl JA, Chaitman BR, Feit F. et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-959.
    CrossrefPubMedGoogle Scholar
  • 36 Lincoff AM, Bittl JA, Harrington RA. et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-863.
    CrossrefPubMedGoogle Scholar
  • 37 Stone GW, McLaurin BT, Cox DA. et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 255: 2203-2216.
    PubMedGoogle Scholar
  • 38 Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994; 343: 311-322.
    CrossrefPubMedGoogle Scholar